CVRx, Inc. Common Stock

The Portnoy Law Firm has initiated a securities fraud investigation into CVRx, Inc. following significant stock declines. The company's stock plummeted 46.3% in April 2025 after reporting weak Q1 revenue of $12.3 million, with management citing early-stage sales representative development. Further declines occurred in May 2025 (38.8%) and Februar...

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Beta Bionics, CVRx, and Navan. Beta Bionics experienced a significant stock price decline of 37% following the announcement of slower-than-expected patient growth in Q4 2025, with new patient starts increasing 36% year-over-year compared to 68% in the prior...

Law firm Bragar Eagel & Squire is investigating CVRx Inc. for potential federal securities law violations following significant stock price declines. CVRx shares dropped 46.3% on April 8, 2025 after the company announced weaker-than-expected Q1 results and disclosed that 25% of territory managers were recently hired. A second decline of 38.8% occ...

CVRx's Barostim device has demonstrated significant reductions in hospital visits and length of stay for heart failure patients, according to new real-world evidence presented at the THT 2025 conference and published in the Journal of Cardiac Failure.

CVRx, a medical device company, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company's Barostim System, which uses neuromodulation to improve heart failure symptoms, has received FDA approval and the CE Mark in the European Economic Area.